Penserra Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Penserra Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,095	Closed	-$25K	–	562
2017 Q1	$25K	Buy	4,095 +1,755	+75%	+$10.9K	﹤0.01%	374
2016 Q4	$14K	Sell	2,340 -200	-8%	-$1.3K	﹤0.01%	736
2016 Q3	$18K	Buy	2,540 +635	+33%	+$4.93K	﹤0.01%	579
2016 Q2	$16K	Buy	1,905 +164	+9%	+$1.4K	﹤0.01%	501
2016 Q1	$11	Buy	1,741 +549	+46%	+$3.68K	﹤0.01%	508
2015 Q4	$10K	Buy	+1,192	New	+$9.03K	﹤0.01%	521

Other funds holding ORMP

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return

Penserra Capital Management's ORMP Position: Q2 2017 in Review

Penserra Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2017, closing a stake of 4,095 shares — an estimated $25K sold.

Penserra Capital Management first reported a position in ORMP in Q4 2015 and held it in 6 quarters. The position peaked at $25K in Q1 2017. 23 funds tracked by Wall St. Rank hold ORMP as of Q2 2017.

Penserra Capital Management reported no remaining Oramed Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Penserra Capital Management sold 4,095 Oramed Pharmaceuticals shares in Q2 2017, an estimated $25K.
Penserra Capital Management first reported a position in Oramed Pharmaceuticals in Q4 2015 and held it in 6 quarters.
Penserra Capital Management's Oramed Pharmaceuticals position peaked at $25K in Q1 2017.
23 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2017.

Based on Penserra Capital Management's 13F filing for Q2 2017, filed 7 Aug 2017.